linjc16/ctgov huggingface dataset:
Ivermectin in Treatment of COVID-19

Study Overview
=================
Brief Summary
-----------------
confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Official Title
-----------------
Use of Ivermectin as a Therapeutic Option for Patients With COVID-19

Conditions
-----------------
COVID

Intervention / Treatment
-----------------
* Drug: Ivermectin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COVID-19 patients during period of the study more than 18 years old Exclusion Criteria: refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ivermectin group<br>group that will receive ivermectin plus standard of care ttt | Drug: Ivermectin<br>* 3 successive days ttt of ivermectin started within 48 hours of symptoms<br>|
| No Intervention: Control group<br>group that will receive standard of care ttt | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to be symptoms free | duration from day 1 symptoms till 3 days without symptoms | within 21 days after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hospitalization | need hospital admission | within 21 days after enrollement | 
| Mechanical ventilation | need mechanical ventilation | within 21 days after enrollement | 
| length of stay | days spent in hospital | within one month days after enrollement | 
| mortality | survived or died | within one month days after enrollement |
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.

Official Title
-----------------
A Twelve-Week, Double-Blind, Placebo-Controlled, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate 1 MG BID for Smoking Cessation

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Drug: varenicline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year. Exclusion Criteria: Subjects who have used bupropion, Zyban, or Wellbutrin previously.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: varenicline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 4 week continuous quit rate ( 4 week CQR ) for weeks 9 -12 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continuous abstinence rate weeks 9-24 |  |  | 
| Long-term Quit Rate at week 24 |  |  | 
| 7 day point prevalence week 12 and 24 |  |  | 
| Results of Minnesota Nicotine Withdrawal Scale |  |  | 
| Brief Questionnaire of Smoking Urges |  |  | 
| Smoking Effects Inventory |  |  |
Obstetricians' Views on the Reasons for Egypt's High Caesarean Section Rates

Study Overview
=================
Brief Summary
-----------------
Handling of questionnaires to a number of obstetricians from different hospitals to show their perceptions about causes of high cs rate in Egypt

Detailed Description
-----------------
An open-ended self-administered questionnaire Handled to a number of obstetricians from different hospitals to show their perceptions about causes of the high cs rate in Egypt.

Official Title
-----------------
Causes of High Caesarean Section Rates in Egypt: Perception of Obstetricians

Conditions
-----------------
Egypt, Caesarean Section Rate

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Obstetricians from different hospitals. - Exclusion Criteria: Refusal to participate -

Ages Eligible for Study
-----------------
Minimum Age: 28 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reasons of the High Caesarean Section Rates in Egypt. | A questionnaire filled by Obstetricians working in Egypt to explore the reasons of high Caesarean Section Rates from their point of view. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Egypt, Caesarean Section, high CS rates, Minia university, Obstetricians
MicroRNA Expression Profile in Human Vitreous of Patients With Various Vitreoretinal Diseases Requiring Vitrectomy

Study Overview
=================
Brief Summary
-----------------
MicroRNAs are important regulators of many cellular functions but their expression profile in human vitreous is still unclear. Aim of this study is to investigate microRNA expression profile by PCR in human vitreous of patients with various vitreoretinal disorders and compare with that of patients with macular holes which are suggested to be similar to that of healthy subjects.

Conditions
-----------------
MicroRNA Expression Profile in Human Vitreous of Various Vitreoretinal Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: any patients undergoing vitrectomy for various vitreoretinal diseases Exclusion Criteria: previously vitrectomized eyes
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| human vitreous, human blood serum, PCR<br>human vitreous and blood serum sampling, PCR 1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MicroRNA expression profile in human vitreous investigated by PCR |  | 1month |
Assessment of Teleconsulting in Nursing Homes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether teleconsulting would be effective and cost-effective by reducing the patients transportations and the use of emergency units for nursing home residents requiring emergent or elective care.

Official Title
-----------------
Assessment of Teleconsulting in Nursing Homes

Conditions
-----------------
Functionally-Impaired Elderly

Intervention / Treatment
-----------------
* Device: Residents of nursing homes with telemedicine after implementation of telemedicine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All residents of selected nursing homes Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group before telemedicine<br>Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine | |
| Control group after telemedicine<br>Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine | |
| Exposed group, before telemedicine<br>Residents of nursing homes with telemedicine prior implementation of telemedicine | |
| Exposed group, after telemedicine<br>Residents of nursing homes with telemedicine after implementation of telemedicine | Device: Residents of nursing homes with telemedicine after implementation of telemedicine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient transportation to a emergency unit |  | Within 1 year after start of the study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Transportation of the patient for a consultation |  | Within 1 year after start of the study | 
| Mean length of hospital stay |  | Within 1 year after start of the study | 
| Number of hospitalizations |  | Within 1 year after start of the study | 
| Overall costs |  | Within 1 year after start of the study |
EARLY-MYO-SEPSIS Registry

Study Overview
=================
Brief Summary
-----------------
The diagnosis and pathophysiology of sepsis-induced cardiac dysfunction remain unknown. This registry is to evaluate characteristics of sepsis patients by multi-modalities imaging, including echocardiography, cardiovascular magnetic resonance imaging in 300 patients in 5 sites. Subjects will be followed up to 2 years.

Detailed Description
-----------------
Approximately 20-30 million patients worldwide suffer from sepsis every year, which is increasing at the rate of 8% to 13% per year. It is possible that sepsis progress to multiple organ dysfunction in the early stage, with a fatality of 30% to 60%. Myocardium is one of the most vulnerable tissue under the abnormal 'inflammation storm'.Cardiac dysfunction is one of the important predictors for mortality of sepsis.Patients with myocardial depression have an apparently higher mortality rate (70%) as compared with septic patients without cardiac impairment (20%). Although several trials had explored the diagnosis and treatment of sepsis-induced cardiac dysfunction, the effective characteristic depict and effective therapy remain incompletely understand. This is a prospective, multi-center, non-randomized, observational registry study of sepsis patients that undergo multi-modality imaging.

Official Title
-----------------
EARLY-MYO-SEPSIS (EARLY Assessment of MYOcardial Injury in Sepsis Patient) Registry

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patiants meets the criteria of Sepsis 3.0 as below: Sepsis is a lifethreatening organ dysfunction caused by a dysregulated host response to infection 1 patients in ICU： 1.1 have at least one organ dysfunction 1.2 SOFA score ≥2 2 patients not in ICU 2.1 have at least one organ dysfunction 2.2 SOFA score or qSOFA score ≥2 Exclusion Criteria: 1. Patient who is unable to comply with the follow-up schedule. 2. Patient who has any medical conditions that in the opinion of the investigators will not be appropriate to participate in the study. 3. Patient has a life expectancy of less than 6 months due to any condition

Ages Eligible for Study
-----------------
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| composite of death, stroke, heart failure | composite of death, stroke, heart failure | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| day of hospitalization | day from admission to discharge | through study completion, 2 months |
Transversus Abdominis Plane Block and Inguinal Hernia Repair

Study Overview
=================
Brief Summary
-----------------
This prospective, randomized, double blinded, placebo-controlled study is designed to evaluate the postoperative analgesic efficacy of the ultrasound-guided transversus abdominis plane block with ropivacaine 0,75 %, in patients undergoing unilateral inguinal hernia repair with a mesh under general anaesthesia, and how the efficiency of early postoperative analgesia achieved correlates with the risk of developing a chronic pain state, a not uncommon condition after this type of surgery.

Official Title
-----------------
The Analgesic Efficacy of the Ultrasound Guided Transversus Abdominis Plane Block After Inguinal Hernia Repair With a Mesh.

Conditions
-----------------
Inguinal Hernia, Abdominal Wall Muscles, Regional Anesthesia, Postoperative Pain

Intervention / Treatment
-----------------
* Procedure: Transversus abdominis plane block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-III patients undergoing inguinal hernia repair with a mesh age between 18 and 75 years old ability to read and write greek - Exclusion Criteria: Inability to consent to the study BMI >40kg/m2 Skin infection at the puncture site Contraindication to mono-amide local anaesthetics, paracetamol, NSAID's (parecoxib) Preoperative use of opioids or NSAID's for chronic pain conditions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Transversus abdominis plane block with 20 ml ropivacaine 0,75%<br>Transversus abdominis plane block with 20 ml ropivacaine 0,75% | Procedure: Transversus abdominis plane block<br>* ultrasound guided transversus abdominis plane block<br>|
| Placebo Comparator: Transversus abdominis plane block with 20 ml saline<br>Transversus abdominis plane block with 20 ml saline | Procedure: Transversus abdominis plane block<br>* ultrasound guided transversus abdominis plane block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain scores at rest and with movement using the numerical rating scale (NRS) |  | 3, 6 and 24 hours postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of chronic pain |  | 6 months after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transversus abdominis plane block, inguinal hernia repair, acute postoperative pain, neuropathic pain
The Effect of Oxygen Administration on Regional Cerebral Oxygen Saturation (rSO2) in the Non-block Side After Stellate Ganglion Block

Study Overview
=================
Brief Summary
-----------------
Stellate ganglion block (SGB) is known to increase blood flow to the innervation area of the stellate ganglion. Near infrared spectroscopy reflects changes of blood volume and allows continuous, non-invasive, and bedside monitoring of regional cerebral oxygen saturation (rSO2). Previous studies have shown the increment of the rSO2 on the block side from the baseline and the decrement of the rSO2 on the non-block side after SGB. Patients with cerebral vascular disease undergoing SGB might be at risk a decrease in cerebral blood flow in the non-block side. The investigators researched the effect of oxygen administration on rSO2 in the non-block side using a near infrared spectroscopy after SGB. 5 L/min oxygen was supplied via nasal cannula from 15 minutes after SGB. The rSO2 in the non-block side were measured before SGB and 5, 10, 15, 20, 25 and 30 minutes after SGB. The present study suggests that oxygen administration can increase the rSO2 of non-block side. In conclusion, it is our belief that oxygen supplement is helpful to the patient with cerebral vascular disease during SGB.

Conditions
-----------------
SSNHL(Sudden Sensory Neural Hearing Loss)

Intervention / Treatment
-----------------
* Procedure: oxygen administration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages between 20 and 70 years ASA PS 1,2 disease entity : pain in the head, neck, upper extremity, and SSNHL ( sudden sensory neural hearing loss ) Exclusion Criteria: patient with the tendency to bleed patient who had cerebrovascular disease patient with respiratory disease ( COPD: chronic obstructive lung disease ) patients who do not give written informed consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: non-block side<br> | Procedure: oxygen administration<br>* nasal O2 5L/min via nasal cannula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| increase on the regional cerebral oxygen saturation | The rSO2 on the non-block side after SGB and additional oxygen administration will be compared with the baseline rSO2. | 5 minutes after oxygen administration |
Changing Lifestyle in Children

Study Overview
=================
Brief Summary
-----------------
A lifestyle intervention aimed at improving exercise levels in primary school children.

Official Title
-----------------
Changing Lifestyle in Children: All Change: Can This Reduce Cardiovascular Risk?

Conditions
-----------------
Cardiovascular Risk

Intervention / Treatment
-----------------
* Behavioral: Eating habits, diet and exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Children 9-11 yrs Exclusion Criteria: Children <9 yrs and >12 yrs

Ages Eligible for Study
-----------------
Minimum Age: 9 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>Active | Behavioral: Eating habits, diet and exercise<br>* Programme of change to eating habits, diet and exercise<br>|
| Experimental: Active 2<br>Active | Behavioral: Eating habits, diet and exercise<br>* Programme of change to eating habits, diet and exercise<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Can an acceptable strategy, based on social cultural factors that influence adherence to the strategy and designed for altering lifestyle associated with CV risk (ALL CHANGE) be developed for school aged children? |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Is ALL CHANGE more effective in altering lifestyle than conventional health education delivered as part of the school curriculum? |  |  |
Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This is a study to evaluate the efficacy of rTMS for relief of obsessive-compulsive symptoms in patients with schizophrenia.

Conditions
-----------------
Schizophrenia, Obsessive-Compulsive Symptoms

Intervention / Treatment
-----------------
* Device: Active rTMS
* Device: SHAM rTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Schizophrenia (DSM-IV-TR) YBOCS ≥ 16 Exclusion Criteria: Mental Retardation Substance abuse Any contraindication to rTMS

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Active rTMS<br>rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions. | Device: Active rTMS<br>* rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.<br>|
| Sham Comparator: Sham<br>Sham stimulation, 20 minutes per session, total 20 sessions | Device: SHAM rTMS<br>* Sham rTMS, without brain stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Obsessive Compulsive symptoms (using Yale-Brown Obsessive Compulsive Scale - Y-BOCS) |  | Baseline, after 20 rTMS sessions (an expected average of 4 weeks), and 4 weeks after end of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of Psychotic Symptoms (using Brief Psychiatric Rating Scale - BPRS) |  | Baseline, after 20 rTMS sessions (an expected average of 4 weeks), and 4 weeks after end of treatment | 
| Change of Brain-Derived Neurotrophic Factor (BDNF) |  | Baseline, after 20 rTMS sessions (an expected average of 4 weeks), and 4 weeks after end of treatment |